Search Results - "Tomic, Davorka"

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response by Kuhle, Jens, Kropshofer, Harald, Haering, Dieter A, Kundu, Uma, Meinert, Rolf, Barro, Christian, Dahlke, Frank, Tomic, Davorka, Leppert, David, Kappos, Ludwig

“…OBJECTIVETo assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its…”
Get full text

Ofatumumab versus Teriflunomide in Multiple Sclerosis by Hauser, Stephen L, Bar-Or, Amit, Cohen, Jeffrey A, Comi, Giancarlo, Correale, Jorge, Coyle, Patricia K, Cross, Anne H, de Seze, Jerome, Leppert, David, Montalban, Xavier, Selmaj, Krzysztof, Wiendl, Heinz, Kerloeguen, Cecile, Willi, Roman, Li, Bingbing, Kakarieka, Algirdas, Tomic, Davorka, Goodyear, Alexandra, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Merschhemke, Martin, Kappos, Ludwig

“…In two identical trials involving a total of 1882 patients with multiple sclerosis, the human anti-CD20 monoclonal antibody ofatumumab was associated with a…”
Get full text

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study by Jakimovski, Dejan, Zivadinov, Robert, Ramanthan, Murali, Hagemeier, Jesper, Weinstock-Guttman, Bianca, Tomic, Davorka, Kropshofer, Harald, Fuchs, Tom A, Barro, Christian, Leppert, David, Yaldizli, Özgür, Kuhle, Jens, Benedict, Ralph HB

“…Background: A limited number of studies investigated associations between serum neurofilament light chain (sNfL) and cognition in persons with multiple…”
Get full text

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study by Montalban, Xavier, Piasecka-Stryczynska, Karolina, Kuhle, Jens, Benkert, Pascal, Arnold, Douglas L, Weber, Martin S, Seitzinger, Andrea, Guehring, Hans, Shaw, Jamie, Tomic, Davorka, Hyvert, Yann, Harlow, Danielle E, Dyroff, Martin, Wolinsky, Jerry S

“…Background: Evobrutinib – an oral, central nervous system (CNS)-penetrant, and highly selective Bruton’s tyrosine kinase inhibitor – has shown efficacy in a…”
Get full text

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis by Cree, Bruce AC, Magnusson, Baldur, Rouyrre, Nicolas, Fox, Robert J, Giovannoni, Gavin, Vermersch, Patrick, Bar-Or, Amit, Gold, Ralf, Piani Meier, Daniela, Karlsson, Göril, Tomic, Davorka, Wolf, Christian, Dahlke, Frank, Kappos, Ludwig

“…Background: In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. Objective: To…”
Get full text

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor by Bar-Or, Amit, Cross, Anne H, Cunningham, Anthony L, Hyvert, Yann, Seitzinger, Andrea, Gühring, Hans, Drouin, Elise E, Alexandri, Nektaria, Tomic, Davorka, Montalban, Xavier

“…Background: Evobrutinib is an oral, central nervous system (CNS)-penetrant and highly selective covalent Bruton’s tyrosine kinase inhibitor under clinical…”
Get full text

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis by Cree, Bruce AC, Cohen, Jeffrey A, Reder, Anthony T, Tomic, Davorka, Silva, Diego, Piani Meier, Daniela, Laflamme, Annik K, Ritter, Shannon, Leppert, David, Kappos, Ludwig

“…Background: Disease-modifying therapies (DMTs) can reduce the risk of disability worsening in patients with relapsing forms of multiple sclerosis (RMS)…”
Get full text

Forebrain connectivity of the prefrontal cortex in the marmoset monkey (Callithrix jacchus): An anterograde and retrograde tract-tracing study by Roberts, Angela C., Tomic, Davorka L., Parkinson, Caroline H., Roeling, Tom A., Cutter, David J., Robbins, Trevor W., Everitt, Barry J.

“…The cortical and subcortical forebrain connections of the marmoset prefrontal cortex (PFC) were examined by injecting the retrograde tracer, choleratoxin, and…”
Get full text

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis by Tavazzi, Eleonora, Bergsland, Niels, Kuhle, Jens, Jakimovski, Dejan, Ramanathan, Murali, Maceski, Aleksandra M., Tomic, Davorka, Hagemeier, Jesper, Kropshofer, Harald, Leppert, David, Dwyer, Michael G., Weinstock-Guttman, Bianca, Benedict, Ralph H. B., Zivadinov, Robert

“…Background Atrophied T2-lesion volume (LV) is a novel MRI marker representing brain-lesion loss due to atrophy, able to predict long-term disability…”
Get full text

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study by Jakimovski, Dejan, Kuhle, Jens, Ramanathan, Murali, Barro, Christian, Tomic, Davorka, Hagemeier, Jesper, Kropshofer, Harald, Bergsland, Niels, Leppert, David, Dwyer, Michael G., Michalak, Zuzanna, Benedict, Ralph H. B., Weinstock‐Guttman, Bianca, Zivadinov, Robert

“…Background Gray matter (GM) pathology is closely associated with physical and cognitive impairment in persons with multiple sclerosis (PwMS). Similarly, serum…”
Get full text

Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials by D’Souza, Marcus, Heikkilä, Antti, Lorscheider, Johannes, Haller, Vanessa, Kravalis, Kristina, Gysin, Shauna, Fuertes, Nuria Alicia Cerdá, Fricker, Evy, Lam, Elaine, Higgins, Peter, Tomic, Davorka, Papadopoulou, Athina, Kappos, Ludwig

“…Background: The Neurostatus-eEDSS is an electronic tool providing automated real-time feedback on inconsistencies of Neurostatus-EDSS calculations. Objective:…”
Get full text

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS by Sormani, Maria Pia, Haering, Dieter A., Kropshofer, Harald, Leppert, David, Kundu, Uma, Barro, Christian, Kappos, Ludwig, Tomic, Davorka, Kuhle, Jens

“…Objectives To assess whether neurofilament light chain (NfL) could serve as an informative endpoint in Phase 2 studies in patients with relapsing–remitting…”
Get full text

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset by Altermatt, Anna, Gaetano, Laura, Magon, Stefano, Häring, Dieter A., Tomic, Davorka, Wuerfel, Jens, Radue, Ernst-Wilhelm, Kappos, Ludwig, Sprenger, Till

“…There is a limited correlation between white matter (WM) lesion load as determined by magnetic resonance imaging and disability in multiple sclerosis (MS). The…”
Get full text

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study by Butzkueven, Helmut, Giacomini, Paul S, Cohan, Stanley, Ziemssen, Tjalf, Sienkiewicz, Daniel, Zhang, Ying, Geissbühler, Yvonne, Silva, Diego, Tomic, Davorka, Kropshofer, Harald, Trojano, Maria

“…Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other…”
Get full text

White matter lesion location correlates with disability in relapsing multiple sclerosis by Gaetano, Laura, Magnusson, Baldur, Kindalova, Petya, Tomic, Davorka, Silva, Diego, Altermatt, Anna, Magon, Stefano, Müller-Lenke, Nicole, Radue, Ernst-Wilhelm, Leppert, David, Kappos, Ludwig, Wuerfel, Jens, Häring, Dieter A, Sprenger, Till

“…Background Lesion location is a prognostic factor of disease progression and disability accrual. Objective To investigate lesion formation in 11 brain regions,…”
Get full text

The Role of the Primate Amygdala in Conditioned Reinforcement by Parkinson, John A, Crofts, Harriet S, McGuigan, Mike, Tomic, Davorka L, Everitt, Barry J, Roberts, Angela C

“…Conditioned reinforcement refers to the capacity of a conditioned stimulus to support instrumental behavior by acquiring affective properties of the primary…”
Get full text

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis by Giovannoni, Gavin, Tomic, Davorka, Bright, Jeremy R, Havrdová, Eva

“…Using combined endpoints to define no evident disease activity (NEDA) is becoming increasingly common when setting targets for treatment outcomes in multiple…”
Get full text

Optimizing treatment success in multiple sclerosis by Ziemssen, Tjalf, Derfuss, Tobias, de Stefano, Nicola, Giovannoni, Gavin, Palavra, Filipe, Tomic, Davorka, Vollmer, Tim, Schippling, Sven

“…Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the introduction of several disease-modifying therapies (DMTs), the…”
Get full text

Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial by Arnold, Douglas L, Elliott, Colm, Martin, Emily C, Hyvert, Yann, Tomic, Davorka, Montalban, Xavier

“…Chronic active lesions (CALs) are demyelinated multiple sclerosis (MS) lesions with ongoing microglia/macrophage activity, resulting in irreversible neuronal…”
Get full text

Neurofilament Light Chain Levels and Disease Activity During Long-Term Treatment of Relapsing Multiple Sclerosis with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (P1-3.011) by Kuhle, Jens, Kappos, Ludwig, Montalban, Xavier, Benkert, Pascal, Li, Ying, Thangavelu, Karthinathan, Hyvert, Yann, Tomic, Davorka

“…Abstract only…”
Get full text